Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- Majority of New Jerseyans Worried About Medical and Health Care Costs.
- NJACTS Community Engagement Core COVID-19 Resources
- With Drowning for Children on the Rise, a Rutgers Heath Expert Discusses Water Safety.
- Researcher Teams Up With Teen Champion Figure Skater to Discover Potential Treatments for Addiction Disorders.
- New Jersey Ranks Near the Bottom on Pay Equity for Mothers.
Categories
- Community (1,934)
- Covid (970)
- CTO Events (1)
- News (2,477)
- Pilots (20)